COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN CATALONIA

被引：0
|
作者：
Mistry, C. [1 ]
Tilley, L. [2 ]
Comin-Colet, J. [2 ]
Vitale, G. [3 ]
Gaugris, S. [1 ]
Jakouloff, D. [4 ]
机构：
[1] FIECON Ltd, St Albans, England
[2] Hosp Univ Bellvitge, Barcelona, Spain
[3] Amarin Spain & Portugal, Madrid, Spain
[4] Amarin Switzerland GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE611
引用
收藏
页码：S175 / S176
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF ICOSAPENT ETHYL (IPE) FOR THE REDUCTION OF THE RISK OF ISCHEMIC CARDIOVASCULAR EVENTS IN CANADA.
    Lachaine, J.
    Charron, J. N.
    Gregoire, J. C.
    Hegele, R. A.
    Leiter, L. A.
    VALUE IN HEALTH, 2020, 23 : S496 - S496
  • [32] Cost-Effectiveness of Fondaparinux in Patients with Acute Coronary Syndrome without ST-Segment Elevation
    Pepe, Camila
    Machado, Marcio
    Olimpio, Alexandre
    Ramos, Rui
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2012, 99 (01) : 613 - 622
  • [33] Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia
    Mejia, Aurelio
    Manuel, Juan, Sr.
    Ceballos, Mateo
    Atehortua, Sara
    Manuel Toro, Juan
    Saldarriaga, Clara
    Elena Mejia, Maria
    Ramirez, Carolina
    BIOMEDICA, 2015, 35 (04): : 531 - 540
  • [34] ANALYSIS OF COST-EFFECTIVENESS AND COST-BENEFIT OF THE RIVAROXABAN ADDITION IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME IN COLOMBIA
    Romero, M.
    Marrugo, R.
    Paez, M. L.
    VALUE IN HEALTH, 2015, 18 (07) : A830 - A830
  • [35] Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
    Michaeli, Daniel Tobias
    Michaeli, Julia Caroline
    Boch, Tobias
    Michaeli, Thomas
    CLINICAL DRUG INVESTIGATION, 2022, 42 (08) : 643 - 656
  • [36] Cost-effectiveness of ticagrelor in acute coronary syndromes
    Henriksson, Martin
    Janzon, Magnus
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (01) : 9 - 18
  • [37] Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain
    Ladapo, Joseph A.
    Hoffmann, Udo
    Bamberg, Fabian
    Nagurney, John T.
    Cutler, David M.
    Weinstein, Milton C.
    Gazelle, G. Scott
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 191 (02) : 455 - 463
  • [38] Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
    Daniel Tobias Michaeli
    Julia Caroline Michaeli
    Tobias Boch
    Thomas Michaeli
    Clinical Drug Investigation, 2022, 42 : 643 - 656
  • [39] The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
    Ademi, Zanfina
    Ofori-Asenso, Richard
    Zomer, Ella
    Owen, Alice
    Liew, Danny
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) : 897 - 904
  • [40] COST-EFFECTIVENESS OF UNIVERSAL VERSUS ASSAY-DRIVEN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME PATIENTS
    Coleman, C., I
    Limone, B. L.
    VALUE IN HEALTH, 2013, 16 (03) : A284 - A284
12345